ProMIS Neurosciences Inc(PMN) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -13.43 | Insider Own | 21.59% | Shs Outstand | 9.0M | Perf Week | -4.11% |
| Market Cap | 0.12B | Forward P/E | - | EPS next Y | 25.36% | Insider Trans | 0.33% | Shs Float | 7.0M | Perf Month | -10.49% |
| Enterprise Value | 0.07B | PEG | - | EPS next Q | -1.27 | Inst Own | 60.8% | Short Float | 4% | Perf Quarter | 31.37% |
| Income | -0.04B | P/S | - | EPS this Y | 77.42% | Inst Trans | 0.74% | Short Ratio | 3.24 | Perf Half Y | -33.3% |
| Sales | 0.00B | P/B | 2.43 | EPS next 5Y | 47.77% | ROA | -127.57% | Short Interest | 0.28M | Perf YTD | 96.34% |
| Book/sh | 5.51 | P/C | 2.25 | EPS past 3/5Y | 27.86% -0.39% | ROE | -172.3% | 52W High | -51.09% ($27.40) | Perf Year | 34% |
| Cash/sh | 5.96 | P/FCF | - | Sales past 3/5Y | - | ROIC | -85.48% | 52W Low | 113.72% ($6.27) | Perf 3Y | -71.11% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -169.38% | Gross Margin | - | Volatility(W/M) | 11.17% 7.93% | Perf 5Y | -94.26% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 1.25 | Perf 10Y | -92.09% |
| Dividend Ex-Date | - | Quick Ratio | 7.85 | EPS Q/Q | 82.32% | Profit Margin | - | RSI (14) | 47.51 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 7.85 | Sales Q/Q | - | SMA20 | -4.95% ($14.1) | Beta | -0.28 | Target Price | $43.5 |
| Payout | - | Debt/Eq | 0 | Earnings | 2026/8/13 | SMA50 | -4.01% ($13.96) | Rel Volume | 0.62 | Prev Close | $14.36 |
| Employees | 11 | LT Debt/Eq | 0 | EPS/Sales Surpr. | 7.15% - | SMA200 | 7.25% ($12.49) | Avg Volume(3M) | 0.09M | Price | $13.4 |
| IPO | 2007/1/16 | Option/Short | No/Yes | Trades | 775 | Volume | 54,089 | Change | -6.72% |
Company
PMN is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
🧠 This is a clinical-stage biotech developing antibodies to treat neurodegenerative diseases such as Alzheimer's and ALS. Using proprietary computational modeling technology, it designs antibodies that selectively target only the toxic protein clumps (oligomers). Its Alzheimer's treatment, PMN310, is currently in a Phase 1b clinical trial, and it also holds a pipeline for ALS and multiple system atrophy.
Over the past 1 year, roughly in the middle
51% below its 1-year high.
PMN has weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +77.4% this year.
Tap to view numbers
The price looks about right
Trading at - times earnings.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
The outlook is positive
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Would have changed by -71.1% if bought 5 years ago.
Tap to view numbers
Dividends are hard to expect
This stock does not pay dividends
Ownership looks stable
Institutions hold 60.8%.
Tap to view numbers
It ranks #4 in the industry
Based on market cap of $120M.
PMN $120M PER -
VRTX $130B PER 29.9
REGN $82B PER 19.6
ARGX $62B PER 37.5
FAQ
What kind of company is PMN?
PMN belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of PMN?
The market cap of PMN is approximately $120M, ranking 4,453 within its sector.
What is the 52-week high and low for PMN?
PMN has recorded a 52-week high of $27.40 and a low of $6.27.
